Evidence map›Paper›PMID 42557391›Full record

ArticleMolecular psychiatry2026

The HDAC inhibitor sodium butyrate moderately enhances long-term fear extinction memory retrieval in humans.

Camille Ribbens, Lisa Peeters, Lukas Van Oudenhove, Bram Vervliet, Boushra Dalile

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Camille RibbensBrain Research on Affective Mechanisms (BRAMLab), Research Unit Brain & Cognition, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0009-0004-7548-3462
Lisa PeetersBrain Research on Affective Mechanisms (BRAMLab), Research Unit Brain & Cognition, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.
Lukas Van OudenhoveLaboratory for Brain-Gut Axis Studies (LaBGAS), Translational Research Center in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, Faculty of Medicine, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-6540-3113
Bram VervlietBrain Research on Affective Mechanisms (BRAMLab), Research Unit Brain & Cognition, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5904-4257
Boushra DalileBrain Research on Affective Mechanisms (BRAMLab), Research Unit Brain & Cognition, Faculty of Psychology and Educational Sciences, KU Leuven, Leuven, Belgium. boushra.dalile@kuleuven.be.ORCID http://orcid.org/0000-0003-1064-7214

Funding

Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 12AZE24NOnderzoeksraad, KU Leuven (Research Council, KU Leuven) POR/23/006
6 · The paper itself

Abstract

Fear extinction and its persistence depend on epigenetic modifications, which can be potentiated by histone deacetylase inhibitors (HDACis). Butyrate (NaBu), a short-chain fatty acid and endogenous HDACi, promotes persistent fear extinction in rodent models by increasing histone acetylation in promoter regions of plasticity- and memory-related genes, thereby enhancing their transcription. To test translational relevance in humans, we conducted a six-arm randomized, triple-blind, placebo-controlled intervention study in 180 healthy participants who underwent a 3-day Pavlovian fear conditioning paradigm. Participants ingested a single dose of NaBu or placebo either before or after extinction learning, the duration of which was additionally manipulated by varying the number of learning trials. NaBu facilitated later retrieval of extinction memory after seven days, both when administered before or after extinction learning, but it did not prevent return of fear during a subsequent reinstatement test. Interestingly, NaBu's effects were contingent on robust extinction learning, emerging only when participants had been exposed to a high number of trials. As no side effects were observed with acute administration of the current dose, these findings support investigating NaBu as a potential adjunct for enhancing extinction-based interventions, such as prolonged exposure therapy, in anxiety disorders.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.